Pharma Mar, S.A.

MCE:PHM.MC

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💊 Pharmaceuticals

Location

Spain

Market Cap

USD 1.62 B

Share Price

USD 94.07

Avg Daily Volume

56,580

Change (1 day)

-0.01%

Change (1 year)

156.28%

Change (YTD)

13.84%

Pharma Mar, S.A. Total Assets for the year ending December 31, 2024: USD 362.05 M

Pharma Mar, S.A. Total Assets is USD 362.05 M for the year ending December 31, 2024, a -3.67% change year over year. Total assets are the total value of all assets owned by a company, representing its resources.

Pharma Mar, S.A. Total Assets for the year ending December 31, 2023 was USD 375.85 M, a -10.67% change year over year.
Pharma Mar, S.A. Total Assets for the year ending December 31, 2022 was USD 420.76 M, a 0.34% change year over year.
Pharma Mar, S.A. Total Assets for the year ending December 31, 2021 was USD 419.35 M, a 3.95% change year over year.
Pharma Mar, S.A. Total Assets for the year ending December 31, 2020 was USD 403.43 M, a 188.28% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Total Assets	Accounts Payable	Short-Term Debt	Long-Term Debt

MCE: PHM.MC

Pharma Mar, S.A.

CEO	Mr. Jose Maria Fernandez Sousa-Faro Ph.D.
IPO Date	Sept. 8, 2000
Location	Spain
Headquarters	Avenida de los Reyes, 1
Employees	500
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 💊 Pharmaceuticals

Description

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.